Global X CleanTech vs Novavax Inc — how do they compare? Global X CleanTech trades at $58.44, while Novavax Inc trades at $7.96 (market cap $1.30B). The key difference: Global X CleanTech is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| CTEC | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $78.11 | $11.19 |
52-Week Low | $41.08 | $6.22 |
Market Cap | — | $1.30B |
Enterprise Value | — | $879.40M |
Signals from Pluang's Aura AI — not financial advice
CTEC trades at $58.40, up 2.1% today, with a neutral technical signal overall. Moving averages suggest a bullish trend, while oscillators are neutral. The stock faces resistance near $60 and support at $53. A dividend of $0.07 is scheduled for July 2026. Key financial ratios are currently unavailable.
The outlook hinges on upcoming financial disclosures to assess fundamentals. Near-term price action may test resistance at $60. Risks include lack of recent financial data and market volatility. Investor sentiment appears balanced pending further company updates.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Trailing returns across standard periods
CTEC invests in companies at the forefront of the clean technology industry. It focuses on disruptive innovations in renewable energy production, energy storage, smart grids, and energy efficiency, with top holdings like Enphase and First Solar.
Read more on CTEC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →